Regarding how to choose the first-line drug for the treatment of psoriasis and AS comorbidity, it has been pointed out (Yang et al., 2016) that compared with local treatment/phototherapy, methotrexate treatment with a TNF-α inhibitor was associated with a significantly lower risk of cardiovascular events compared with treatment with MTX. Here, TNF is linked to psoriasis.